UPDATE: Tarsus Pharmaceuticals Q3 Adj. EPS $(0.78) Beats $(2.73) Estimate, Sales $194.569M Beat $186.598M Estimate
Benzinga Newsdesk 15 hours ago
NewsEarningsEarnings Beats
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses of $(0.30) per share
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(2.73) by 71.43 percent. This is a 160 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $194.569 million which beat the analyst consensus estimate of $186.598 million by 4.27 percent. This is a 63.92 percent increase over sales of $118.697 million the same period last year.